A Phase 1, Randomized, Placebo-and Positive-controlled Crossover Study To Determine The Effect Of Single-dose Pf-04965842 On Qtc Interval In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2018
At a glance
- Drugs Abrocitinib (Primary) ; Moxifloxacin
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Pfizer
- 11 Oct 2018 Status changed from recruiting to completed.
- 04 Oct 2018 Planned End Date changed from 21 Sep 2018 to 1 Oct 2018.
- 04 Oct 2018 Planned primary completion date changed from 21 Sep 2018 to 1 Oct 2018.